by Zena Sfeir | Aug 10, 2022 | News
GNS Co-Founder Iya Khalil weighed in on how using AI and big data will transform medicine and healthcare and help “drug hunters” succeed. Watch her talk on CNN Video here.
by Zena Sfeir | Jul 14, 2022 | News
Panel discussion at Bio conference 2022 entitled: Why the FDA will bet more on in silico simulations to trigger better success rates for NDAs. The session was moderated by Colin Hill and showcased recent examples in digital, AI, and in-silico models that highlight...
by Zena Sfeir | Jun 16, 2022 | News
With just 10% of therapeutic programs successfully moving from first toxicity dose to market, drug developers are on a constant hunt for new tricks to put the odds in their favor. Strategies abound, from biomarker-guided patient selection to deeper regulatory...
by Zena Sfeir | Jun 3, 2022 | News
The COVID-19 pandemic drove huge shifts in clinical trial practice and the transformation is expected to continue even after the global health emergency abates. Industry leaders sharing their predictions around clinical development homed in on decentralized trials,...
by Zena Sfeir | Jun 3, 2022 | News
CB Insights listed the 12 Tech Trends To Watch Closely In 2022. For potentially life-saving drugs and treatments, the road to commercialization is steep. Virtualizing the clinical trial is listed as a tech trend to accelerate drugs discovery and development. As per CB...
by Zena Sfeir | Apr 15, 2021 | News
Pharmaceutical Executive reporter discusses how a coalition of data, computational power, and AI is bringing the full potential of in silico medicine out of the realm of science fiction. Read the full story here.
